According to the latest report by IMARC Group, titled "Spinal Muscular Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033," the global spinal muscular atrophy market size is witnessing steady growth. Spinal muscular atrophy is a genetic disorder that affects the nerves responsible for controlling voluntary muscles. It is a progressive condition that can cause muscle weakness and atrophy, or shrinkage, leading to difficulties with movement, breathing, and swallowing. SMA is caused by a defect in the survival motor neuron 1 (SMN1) gene, resulting in an SMN protein deficiency. This protein is essential for the survival and function of motor neurons responsible for sending signals from the brain to the muscles. Some of the treatment options for SMA include medications, such as nusinersen and onasemnogene abeparvovec, that aim to increase the production of the SMN protein. Physical therapy and assistive devices, such as braces and wheelchairs, may also manage symptoms and improve quality of life. Gene therapy, which involves replacing or repairing the defective SMN1 gene, is also being investigated as a potential treatment option for SMA.
Global Spinal Muscular Atrophy Market Trends:
The global market is majorly driven by the increasing prevalence of spinal muscular atrophy. In line with this, the development of innovative therapies for its treatment is significantly contributing to the market growth. Furthermore, the availability of advanced healthcare infrastructure is positively influencing the market. Apart from this, the rising awareness and access to innovative therapies are catalyzing the market. Moreover, the key companies are focusing on developing innovative therapies for SMA and investing in research and development to improve treatment options. Besides, the rapid advancements in gene therapy and drug therapy are expected to create a positive outlook for the market. Additionally, the growing approval of new disease-modifying therapies is projected to provide a boost to the market. Some of the other factors driving the market include the increasing product launches, rising research and development initiatives, and growing access to the reimbursement of expensive drugs globally.
- On the basis of the marketed products, the market has been categorized into Evrysdi (Risdiplam) - PTC Therapeutics/Roche, Spinraza (Nusinersen) - Biogen/Ionis Pharmaceuticals, and Zolgensma (Onasemnogene abeparvovec) - Novartis Gene Therapies/Nationwide Children's Hospital.
- Based on the pipeline drugs, the market has been classified into RG 6237 - Hoffmann-La Roche, SRK015 - Scholar Rock and ACTX 401 - Alcyone Therapeutics.
- On the basis of the region, the market has been divided into the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan.
- The competitive landscape of the market has been studied in the report with detailed profiles of the key players operating in the market.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800